Neratinib (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Neratinib" in English language version.

refsWebsite

Global rank English rank

13nih.gov

4^th place

7doi.org

2^nd place

4fda.gov

447^th place

338^th place

1hres.ca

low place

1medicines.org.uk

3,823^rd place

2,387^th place

1europa.eu

68^th place

117^th place

1semanticscholar.org

11^th place

8^th place

1harvard.edu

18^th place

17^th place

1genengnews.com

low place

6,625^th place

1com.bd

low place

com.bd

medex.com.bd

"Hernix". medex.com.bd. Retrieved 14 July 2021.

doi.org

Baselga J, Coleman RE, Cortés J, Janni W (November 2017). "Advances in the management of HER2-positive early breast cancer". Critical Reviews in Oncology/Hematology. 119: 113–122. doi:10.1016/j.critrevonc.2017.10.001. PMC 5662944. PMID 29042085.
Minami Y, Shimamura T, Shah K, LaFramboise T, Glatt KA, Liniker E, et al. (July 2007). "The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272". Oncogene. 26 (34): 5023–5027. doi:10.1038/sj.onc.1210292. PMID 17311002.
Singh J, Petter RC, Baillie TA, Whitty A (April 2011). "The resurgence of covalent drugs". Nature Reviews. Drug Discovery. 10 (4): 307–317. doi:10.1038/nrd3410. PMID 21455239. S2CID 5819338.
Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. (February 2008). "The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP". Proceedings of the National Academy of Sciences of the United States of America. 105 (6): 2070–2075. Bibcode:2008PNAS..105.2070Y. doi:10.1073/pnas.0709662105. PMC 2538882. PMID 18227510.
Schwab CL, English DP, Black J, Bellone S, Lopez S, Cocco E, et al. (October 2015). "Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo". Gynecologic Oncology. 139 (1): 112–117. doi:10.1016/j.ygyno.2015.08.002. PMC 4587290. PMID 26260909.
Ma Y, Lin Z, Fallon JK, Zhao Q, Liu D, Wang Y, Liu F (November 2015). "New mouse xenograft model modulated by tumor-associated fibroblasts for human multi-drug resistance in cancer". Oncology Reports. 34 (5): 2699–2705. doi:10.3892/or.2015.4265. PMC 4583831. PMID 26352907.
Santamaria S, Gagliani MC, Bellese G, Marconi S, Lechiara A, Dameri M, et al. (July 2021). "Imaging of Endocytic Trafficking and Extracellular Vesicles Released Under Neratinib Treatment in ERBB2⁺ Breast Cancer Cells". The Journal of Histochemistry and Cytochemistry. 69 (7): 461–473. doi:10.1369/00221554211026297. PMC 8246527. PMID 34126793.

europa.eu

ema.europa.eu

"Nerlynx EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 13 November 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

fda.gov

"FDA approves new treatment to reduce the risk of breast cancer returning". U.S. Food and Drug Administration (FDA) (Press release). 17 July 2017. Retrieved 13 November 2020. This article incorporates text from this source, which is in the public domain.
"FDA approves neratinib for extended adjuvant treatment of early stage HER2-positive breast cancer". U.S. Food and Drug Administration (FDA). 17 July 2017. Retrieved 13 November 2020. This article incorporates text from this source, which is in the public domain.
"Drug Trials Snapshot: Nerlynx". U.S. Food and Drug Administration (FDA). 17 July 2017. Retrieved 13 November 2020. This article incorporates text from this source, which is in the public domain.

accessdata.fda.gov

"Nerlynx (neratinib maleate) Tablets". U.S. Food and Drug Administration (FDA). 21 August 2017. Retrieved 13 November 2020.

genengnews.com

"Puma Acquires Global Rights to Pfizer's Phase III Breast Cancer Drug Neratinib". GEN. 6 October 2011.

harvard.edu

ui.adsabs.harvard.edu

Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. (February 2008). "The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP". Proceedings of the National Academy of Sciences of the United States of America. 105 (6): 2070–2075. Bibcode:2008PNAS..105.2070Y. doi:10.1073/pnas.0709662105. PMC 2538882. PMID 18227510.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Nerlynx". Health Canada. 23 October 2014. Retrieved 29 May 2022.

medicines.org.uk

"Nerlynx 40 mg Film-coated Tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 13 November 2020.

nih.gov

pubmed.ncbi.nlm.nih.gov

Baselga J, Coleman RE, Cortés J, Janni W (November 2017). "Advances in the management of HER2-positive early breast cancer". Critical Reviews in Oncology/Hematology. 119: 113–122. doi:10.1016/j.critrevonc.2017.10.001. PMC 5662944. PMID 29042085.
Minami Y, Shimamura T, Shah K, LaFramboise T, Glatt KA, Liniker E, et al. (July 2007). "The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272". Oncogene. 26 (34): 5023–5027. doi:10.1038/sj.onc.1210292. PMID 17311002.
Singh J, Petter RC, Baillie TA, Whitty A (April 2011). "The resurgence of covalent drugs". Nature Reviews. Drug Discovery. 10 (4): 307–317. doi:10.1038/nrd3410. PMID 21455239. S2CID 5819338.
Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. (February 2008). "The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP". Proceedings of the National Academy of Sciences of the United States of America. 105 (6): 2070–2075. Bibcode:2008PNAS..105.2070Y. doi:10.1073/pnas.0709662105. PMC 2538882. PMID 18227510.
Schwab CL, English DP, Black J, Bellone S, Lopez S, Cocco E, et al. (October 2015). "Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo". Gynecologic Oncology. 139 (1): 112–117. doi:10.1016/j.ygyno.2015.08.002. PMC 4587290. PMID 26260909.
Ma Y, Lin Z, Fallon JK, Zhao Q, Liu D, Wang Y, Liu F (November 2015). "New mouse xenograft model modulated by tumor-associated fibroblasts for human multi-drug resistance in cancer". Oncology Reports. 34 (5): 2699–2705. doi:10.3892/or.2015.4265. PMC 4583831. PMID 26352907.
Santamaria S, Gagliani MC, Bellese G, Marconi S, Lechiara A, Dameri M, et al. (July 2021). "Imaging of Endocytic Trafficking and Extracellular Vesicles Released Under Neratinib Treatment in ERBB2⁺ Breast Cancer Cells". The Journal of Histochemistry and Cytochemistry. 69 (7): 461–473. doi:10.1369/00221554211026297. PMC 8246527. PMID 34126793.

ncbi.nlm.nih.gov

Baselga J, Coleman RE, Cortés J, Janni W (November 2017). "Advances in the management of HER2-positive early breast cancer". Critical Reviews in Oncology/Hematology. 119: 113–122. doi:10.1016/j.critrevonc.2017.10.001. PMC 5662944. PMID 29042085.
Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. (February 2008). "The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP". Proceedings of the National Academy of Sciences of the United States of America. 105 (6): 2070–2075. Bibcode:2008PNAS..105.2070Y. doi:10.1073/pnas.0709662105. PMC 2538882. PMID 18227510.
Schwab CL, English DP, Black J, Bellone S, Lopez S, Cocco E, et al. (October 2015). "Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo". Gynecologic Oncology. 139 (1): 112–117. doi:10.1016/j.ygyno.2015.08.002. PMC 4587290. PMID 26260909.
Ma Y, Lin Z, Fallon JK, Zhao Q, Liu D, Wang Y, Liu F (November 2015). "New mouse xenograft model modulated by tumor-associated fibroblasts for human multi-drug resistance in cancer". Oncology Reports. 34 (5): 2699–2705. doi:10.3892/or.2015.4265. PMC 4583831. PMID 26352907.
Santamaria S, Gagliani MC, Bellese G, Marconi S, Lechiara A, Dameri M, et al. (July 2021). "Imaging of Endocytic Trafficking and Extracellular Vesicles Released Under Neratinib Treatment in ERBB2⁺ Breast Cancer Cells". The Journal of Histochemistry and Cytochemistry. 69 (7): 461–473. doi:10.1369/00221554211026297. PMC 8246527. PMID 34126793.

dailymed.nlm.nih.gov

"Nerlynx- neratinib tablet". DailyMed. 6 August 2020. Retrieved 13 November 2020.

semanticscholar.org

api.semanticscholar.org

Singh J, Petter RC, Baillie TA, Whitty A (April 2011). "The resurgence of covalent drugs". Nature Reviews. Drug Discovery. 10 (4): 307–317. doi:10.1038/nrd3410. PMID 21455239. S2CID 5819338.